FDA Recalls Duloxetine Capsules Over Cancer Risk

FDA Recalls Duloxetine Capsules Over Cancer Risk

1 minute read
Updated 12 hours ago

Recall Details

The has recalled Duloxetine Delayed-Release Capsules produced by Towa Pharmaceutical Europe due to high levels of a cancer-causing chemical, N-nitroso-duloxetine.

Classified as a Class II recall, the action affects thousands of bottles across the , indicating potential temporary or reversible health consequences.

Health Advisory

Patients are advised not to stop their medication without consulting healthcare professionals, despite the recall.

The FDA is investigating the source of the impurities and emphasizes the importance of not discontinuing prescribed medications without professional guidance.
This is a beta feature. We cannot guarantee the accuracy or quality of responses.